Table Info

Table 5.

Summary of all HDAC IC₅₀ values

Molecule name	HDAC protein members IC₅₀ (mol/L)
Molecule name	1	2	3	4	5	6	7	8	9	10	11
Vorinostat	0.06	0.042	0.036	0.02	0.036	0.029	0.129	0.173	0.049	0.060	0.031
Tucidinostat	0.1	0.2	0.1	> 10	> 10	> 10	> 10	0.7	> 10	0.1	0.4
Romidepsin	0.001	0.001	0.001	647	> 1	226	> 1	> 1	> 1	0.001	0.0003
Panobinostat	0.003	0.002	0.002	0.001	0.001	0.001	0.002	0.022	0.001	0.031	0.004
Belinostat	0.026	0.022	0.019	0.015	0.025	0.010	0.051	0.022	0.024	0.059	0.027
Trichostatin A	0.00068	0.0027	0.0004	> 1	0.776	0.00095	0.482	0.207	> 1	0.0016	> 1
Quisinostat	0.00062	0.002	0.00048	0.0046	0.006	0.0399	0.004	0.0024	0.0067	0.002	> 1
Pracinostat*	0.028	0.027	0.019	0.016	0.021	0.247	0.107	0.048	0.024	0.023	0.043
Abexinostat*	0.007	0.019	0.0082	-	-	0.017	-	0.028	-	0.024	-
Fimepinostat	0.0017	0.005	0.0018	0.409	0.647	0.027	0.426	0.191	0.554	0.0028	0.0054
HDAC-IN-30	0.0134	0.028	0.0092	-	-	0.0427	-	0.131	-	-	-
MMH409	-	-	-	-	-	-	-	0.0234	-	-	-
PCI-34051	4	> 50	> 50	> 50	-	-	2.9	0.010	-	13	-
Chidamide	0.095	0.160	0.067	> 10	> 10	> 10	> 10	0.733	> 10	0.078	0.432
Tacdeinaline	0.900	0.900	1.2	-	-	-	-	> 20	-	-	-
Entinostat	0.243	0.453	0.248	> 10	> 10	> 10	> 10	> 10	> 10	> 10	-
BRD-6929	0.001	0.008	0.458	> 10	> 10	> 10	> 10	> 10	> 10	3.4	-
Mocetinostat	0.150	0.290	1.6	> 10	> 10	> 10	> 10	> 10	-	-	0.590
ACY-957	0.007	0.018	1.3	NI	NI	NI	NI	NI	NI	-	-
Compound 1	0.006	0.190	27.7	> 50	-	> 50	-	31.7	-	-	-
BRD-4884	0.029	0.062	1.09	-	-	-	-	-	-	-	-
BRD-3349	0.011	0.049	2.78	-	-	-	-	-	-	-	-
RGFP109	0.300	1.28	0.063	> 180	> 180	>180	> 180	10.7	-	-	-
RGFP136	5.2	3	0.400	> 180	> 180	> 180	> 180	13.2	-	-	-
RGFP966	5.6	9.7	0.210	-	-	-	-	>100	-	-	-
BRD-3308	1.26	1.34	0.054	> 33	> 33	> 33	> 33	> 33	> 33	-	-
BG45	2	2.2	0.289	-	-	> 20	-	-	-	-	-
T326	> 100	-	0.260	>100	-	> 100	-	>100	-	-	-
Compound 2	> 30	>30	0.120	-	-	> 30	-	> 30	-	-	-
Compound 3	0.080	0.110	0.006	> 100	> 100	> 100	> 100	0.0252	> 100	> 2	> 4
UF010	0.500	0.100	0.060	> 100	> 100	9.1	> 100	1.5	> 100	15.3	44.5
SR-4370	0.130	0.580	0.006	-	-	2.3	-	3.7	-	-	-
Compound 4	0.0118	0.0955	0.00095	-	-	-	-	-	-	-	-
Compound 5	0.0633	0.287	0.0085	-	-	> 100	-	-	-	-	-
Compound 6	0.00954	0.028	0.00141	-	-	> 100	-	-	-	-	-
Compound 7	0.00469	0.046	0.00028	> 10	> 10	> 50	> 10	> 1.75	> 10	-	-
Largazole*	0.020	0.021	0.048	-	-	> 1	-	-	-	-	-
Largazole thiol*	0.00007	0.00007	0.000017	-	-	0.025	-	-	-	-	-
Psammaplin A*	0.045	-	-	-	-	2.8	-	-	-	-	-
Psammaplin A thiol	0.0009	-	-	-	-	0.360	-	-	-	-	-
Compound 8	20	31	0.029	> 40	> 40	> 45	> 40	> 45	> 45	10	2
Compound 9	0.0097	0.029	0.0076	-	-	9	-	> 45	-	-	-
Compound 10	0.040	0.061	0.0093	-	-	> 45	-	> 45	-	-	-
Compound 11	0.013	0.018	0.012	-	-	9	-	> 45	-	-	-
Compound 12	0.0001	0.00047	0.000087	-	-	> 45	-	0.016	-	-	-
Compound 13	-	0.500	-	-	-	-	-	-	-	-	-

Structures are present in the tables corresponding to the molecules [9, 14, 19, 21–23, 42, 43, 45–50, 52, 56, 57, 60–68, 71, 73, 74, 78, 80–91]. *: Ki value reported in place of an IC₅₀; NI: no inhibition observed; -: not applicable

Declarations

Author contributions

DIA, EDdA, and PTG: Conceptualization. DIA, NHP, and LSH: Investigation, Data collection. DIA: Writing—original draft. DIA, EDdA, OHK, RM, NHP, LSH, and PTG: Writing—review & editing. DIA, EDdA, OHK, RM, and PTG: Validation. DIA and PTG: Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Yoshida M, Kudo N, Kosono S, Ito A. Chemical and structural biology of protein lysine deacetylases. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93:297–321. [DOI] [PubMed] [PMC]

de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737–49. [DOI] [PubMed] [PMC]

Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20:3898–941. [DOI] [PubMed] [PMC]

Adhikari N, Jha T, Ghosh B. Dissecting histone deacetylase 3 in multiple disease conditions: selective inhibition as a promising therapeutic strategy. J Med Chem. 2021;64:8827–69. [DOI] [PubMed]

Krämer OH. HDAC2: a critical factor in health and disease. Trends Pharmacol Sci. 2009;30:647–55. [DOI] [PubMed]

Millard CJ, Watson PJ, Fairall L, Schwabe JWR. Targeting class I histone deacetylases in a “complex” environment. Trends Pharmacol Sci. 2017;38:363–77. [DOI] [PubMed]

Luo Y, Li H. Structure-based inhibitor discovery of class I histone deacetylases (HDACs). Int J Mol Sci. 2020;21:8828. [DOI] [PubMed] [PMC]

Melesina J, Simoben CV, Praetorius L, Bülbül EF, Robaa D, Sippl W. Strategies to design selective histone deacetylase inhibitors. ChemMedChem. 2021;16:1336–59. [DOI] [PubMed]

Routholla G, Pulya S, Patel T, Abdul Amin S, Adhikari N, Biswas S, et al. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors. Bioorg Chem. 2021;114:105050. [DOI] [PubMed]

10.

Zhao WN, Ghosh B, Tyler M, Lalonde J, Joseph NF, Kosaric N, et al. Class I histone deacetylase inhibition by tianeptinaline modulates neuroplasticity and enhances memory. ACS Chem Neurosci. 2018;9:2262–73. [DOI] [PubMed]

11.

Hirata Y, Sasaki T, Kanki H, Choong CJ, Nishiyama K, Kubo G, et al. New 5-aryl-substituted 2-aminobenzamide-type HDAC inhibitors with a diketopiperazine group and their ameliorating effects on ischemia-induced neuronal cell death. Sci Rep. 2018;8:1400. [DOI] [PubMed] [PMC]

12.

Cao F, Zwinderman MRH, Dekker FJ. The process and strategy for developing selective histone deacetylase 3 inhibitors. Molecules. 2018;23:551. [DOI] [PubMed] [PMC]

13.

Hsieh HY, Chuang HC, Shen FH, Detroja K, Hsin LW, Chen CS. Targeting breast cancer stem cells by novel HDAC3-selective inhibitors. Eur J Med Chem. 2017;140:42–51. [DOI] [PubMed]

14.

Geurs S, Clarisse D, De Bosscher K, D’hooghe M. The zinc-binding group effect: lessons from non-hydroxamic acid vorinostat analogs. J Med Chem. 2023;66:7698–729. [DOI] [PubMed]

15.

Jiang Y, Xu J, Yue K, Huang C, Qin M, Chi D, et al. Potent hydrazide-based HDAC inhibitors with a superior pharmacokinetic profile for efficient treatment of acute myeloid leukemia in vivo. J Med Chem. 2022;65:285–302. [DOI] [PubMed]

16.

Li X, Peterson YK, Inks ES, Himes RA, Li J, Zhang Y, et al. Class I HDAC inhibitors display different antitumor mechanism in leukemia and prostatic cancer cells depending on their p53 status. J Med Chem. 2018;61:2589–603. [DOI] [PubMed] [PMC]

17.

Chou CJ, Herman D, Gottesfeld JM. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem. 2008;283:35402–9. [DOI] [PubMed] [PMC]

18.

Moreno-Yruela C, Olsen CA. Determination of slow-binding HDAC inhibitor potency and subclass selectivity. ACS Med Chem Lett. 2022;13:779–85. [DOI] [PubMed] [PMC]

19.

Moreno-Yruela C, Fass DM, Cheng C, Herz J, Olsen CA, Haggarty SJ. Kinetic tuning of HDAC inhibitors affords potent inducers of progranulin expression. ACS Chem Neurosci. 2019;10:3769–77. [DOI] [PubMed] [PMC]

20.

Ibrahim HS, Abdelsalam M, Zeyn Y, Zessin M, Mustafa AM, Fischer MA, et al. Synthesis, molecular docking and biological characterization of pyrazine linked 2-aminobenzamides as new class I selective histone deacetylase (HDAC) inhibitors with anti-leukemic activity. Int J Mol Sci. 2021;23:369. [DOI] [PubMed] [PMC]

21.

Ho TCS, Chan AHY, Ganesan A. Thirty years of HDAC inhibitors: 2020 insight and hindsight. J Med Chem. 2020;63:12460–84. [DOI] [PubMed]

22.

Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Schiöth HB. Recent developments of HDAC inhibitors: emerging indications and novel molecules. Br J Clin Pharmacol. 2021;87:4577–97. [DOI] [PubMed]

23.

Emmett MJ, Lazar MA. Integrative regulation of physiology by histone deacetylase 3. Nat Rev Mol Cell Biol. 2019;20:102–15. [DOI] [PubMed] [PMC]

24.

Connolly RM, Zhao F, Miller KD, Lee MJ, Piekarz RL, Smith KL, et al. E2112: randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group. J Clin Oncol. 2021;39:3171–81. [DOI] [PubMed] [PMC]

25.

An exploratory study of pembrolizumab plus entinostat in non-inflamed stage III/IV melanoma. Bethesda (MD): U.S. National Library of Medicine; c2019 [cited 2022 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03765229?term=entinostat&recrs=adf&draw=2&rank=5

26.

Single and multiple ascending dose and food effect PK study in healthy adult and elderly subjects. Bethesda (MD): U.S. National Library of Medicine; c2018 [cited 2022 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03668314?term=RDN929&draw=2&rank=2

27.

Study of mocetinostat in selected patients with mutations of acetyltransferase genes in relapsed and refractory diffuse large B-cell lymphoma and follicular lymphoma. Bethesda (MD): U.S. National Library of Medicine; c2014 [cited 2022 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02282358?term=mocetinostat&recrs=adf&draw=2&rank=1

28.

Pembrolizumab (immunotherapy drug) in combination with guadecitabine and mocetinostat (epigenetic drugs) for patients with advanced lung cancer. Bethesda (MD): U.S. National Library of Medicine; c2017 [cited 2022 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03220477?term=mocetinostat&recrs=adf&draw=2&rank=3

29.

Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, et al. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019;3:508–18. [DOI] [PubMed] [PMC]

30.

4SC-201 (resminostat) in advanced colorectal carcinoma (SHORE). Bethesda (MD): U.S. National Library of Medicine; c2011 [cited 2022 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT01277406?term=resminostat&draw=2&rank=5

31.

Phase II sudy of GIVINOSTAT (ITF2357) in combination with hydroxyurea in polycythemia vera (PV). Bethesda (MD): U.S. National Library of Medicine; c2009 [cited 2022 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT00928707?term=Givinostat&draw=2&rank=7

32.

Bettica P, Petrini S, D’Oria V, D’Amico A, Catteruccia M, Pane M, et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26:643–9. [DOI] [PubMed]

33.

Vojinovic J, Damjanov N. HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med. 2011;17:397–403. [DOI] [PubMed] [PMC]

34.

Vojinovic J, Damjanov N, D’Urzo C, Furlan A, Susic G, Pasic S, et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:1452–8. [DOI] [PubMed]

35.

Topical remetinostat in treating patient with cutaneous basal cell cancer. Bethesda (MD): U.S. National Library of Medicine; c2017 [cited 2022 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03180528?term=remetinostat&draw=2&rank=2

36.

A study of OKI-179 in patients with solid tumors. Bethesda (MD): U.S. National Library of Medicine; c2019 [cited 2022 Nov 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03931681?term=oki-179&draw=2&rank=1

37.

Mustafa AHM, Krämer OH. Pharmacological modulation of the crosstalk between aberrant Janus kinase signaling and epigenetic modifiers of the histone deacetylase family to treat cancer. Pharmacol Rev. 2023;75:35–61. [DOI] [PubMed]

38.

Zhang L, Zhang J, Jiang Q, Zhang L, Song W. Zinc binding groups for histone deacetylase inhibitors. J Enzyme Inhib Med Chem. 2018;33:714–21. [DOI] [PubMed] [PMC]

39.

Toutah K, Nawar N, Timonen S, Sorger H, Raouf YS, Bukhari S, et al. Development of HDAC inhibitors exhibiting therapeutic potential in T-cell prolymphocytic leukemia. J Med Chem. 2021;64:8486–509. [DOI] [PubMed] [PMC]

40.

Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 2008;7:854–68. [DOI] [PubMed]

41.

Shen S, Kozikowski AP. Why hydroxamates may not be the best histone deacetylase inhibitors—what some may have forgotten or would rather forget? ChemMedChem. 2016;11:15–21. [DOI] [PubMed] [PMC]

42.

Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther. 2010;9:642–52. [DOI] [PubMed]

43.

Hassan MM, Israelian J, Nawar N, Ganda G, Manaswiyoungkul P, Raouf YS, et al. Characterization of conformationally constrained benzanilide scaffolds for potent and selective HDAC8 targeting. J Med Chem. 2020;63:8634–48. [DOI] [PubMed]

44.

Shouksmith AE, Gawel JM, Nawar N, Sina D, Raouf YS, Bukhari S, et al. Class I/IIb-selective HDAC inhibitor exhibits oral bioavailability and therapeutic efficacy in acute myeloid leukemia. ACS Med Chem Lett. 2019;11:56–64. [DOI] [PubMed] [PMC]

45.

Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008;22:1026–34. [DOI] [PubMed]

46.

Ren Y, Su X, Kong L, Li M, Zhao X, Yu N, et al. Therapeutic effects of histone deacetylase inhibitors in a murine asthma model. Inflamm Res. 2016;65:995–1008. [DOI] [PubMed] [PMC]

47.

Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther. 2006;5:1309–17. [DOI] [PubMed]

48.

Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res. 2012;18:4104–13. [DOI] [PubMed]

49.

Liu Q, Zhang B, Wang Y, Wang X, Gou S. Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway. Eur J Med Chem. 2022;229:114058. [DOI] [PubMed]

50.

Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-κB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 2009;15:3354–65. [DOI] [PubMed] [PMC]

51.

Gawel JM, Shouksmith AE, Raouf YS, Nawar N, Toutah K, Bukhari S, et al. PTG-0861: a novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia. Eur J Med Chem. 2020;201:112411. [DOI] [PubMed]

52.

Singh A, Chang TY, Kaur N, Hsu KC, Yen Y, Lin TE, et al. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. Eur J Med Chem. 2021;215:113169. [DOI] [PubMed]

53.

Olaoye OO, Watson PR, Nawar N, Geletu M, Sedighi A, Bukhari S, et al. Unique molecular interaction with the histone deacetylase 6 catalytic tunnel: crystallographic and biological characterization of a model chemotype. J Med Chem. 2021;64:2691–704. [DOI] [PubMed] [PMC]

54.

Nawar N, Bukhari S, Adile AA, Suk Y, Manaswiyoungkul P, Toutah K, et al. Discovery of HDAC6-selective inhibitor NN-390 with in vitro efficacy in group 3 medulloblastoma. J Med Chem. 2022;65:3193–217. [DOI] [PubMed]

55.

Lauffer BE, Mintzer R, Fong R, Mukund S, Tam C, Zilberleyb I, et al. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem. 2013;288:26926–43. [DOI] [PubMed] [PMC]

56.

Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69:901–9. [DOI] [PubMed]

57.

Moradei OM, Mallais TC, Frechette S, Paquin I, Tessier PE, Leit SM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007;50:5543–6. [DOI] [PubMed]

58.

Ganai SA. Characterizing binding intensity and energetic features of histone deacetylase inhibitor pracinostat towards class I HDAC isozymes through futuristic drug designing strategy. In Silico Pharmacol. 2021;9:18. [DOI] [PubMed] [PMC]

59.

Bressi JC, Jennings AJ, Skene R, Wu Y, Melkus R, De Jong R, et al. Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010;20:3142–5. [DOI] [PubMed]

60.

Witter DJ, Harrington P, Wilson KJ, Chenard M, Fleming JC, Haines B, et al. Optimization of biaryl selective HDAC1&2 inhibitors (SHI-1:2). Bioorg Med Chem Lett. 2008;18:726–31. [DOI] [PubMed]

61.

Schroeder FA, Lewis MC, Fass DM, Wagner FF, Zhang YL, Hennig KM, et al. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS One. 2013;8:e71323. [DOI] [PubMed] [PMC]

62.

Wagner FF, Zhang YL, Fass DM, Joseph N, Gale JP, Weïwer M, et al. Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers. Chem Sci. 2015;6:804–15. [DOI] [PubMed] [PMC]

63.

Shearstone JR, Golonzhka O, Chonkar A, Tamang D, van Duzer JH, Jones SS, et al. Chemical inhibition of histone deacetylases 1 and 2 induces fetal hemoglobin through activation of GATA2. PLoS One. 2016;11:e0153767. [DOI] [PubMed] [PMC]

64.

Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008;7:759–68. [DOI] [PubMed]

65.

Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 2014;28:680–9. [DOI] [PubMed] [PMC]

66.

Barton KM, Archin NM, Keedy KS, Espeseth AS, Zhang YL, Gale J, et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One. 2014;9:e102684. [DOI] [PubMed] [PMC]

67.

Malvaez M, McQuown SC, Rogge GA, Astarabadi M, Jacques V, Carreiro S, et al. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci U S A. 2013;110:2647–52. [DOI] [PubMed] [PMC]

68.

Bourguet E, Ozdarska K, Moroy G, Jeanblanc J, Naassila M. Class I HDAC inhibitors: potential new epigenetic therapeutics for alcohol use disorder (AUD). J Med Chem. 2018;61:1745–66. [DOI] [PubMed]

69.

Beyer M, Romanski A, Mustafa AM, Pons M, Büchler I, Vogel A, et al. HDAC3 activity is essential for human leukemic cell growth and the expression of β-catenin, MYC, and WT1. Cancers (Basel). 2019;11:1436. [DOI] [PubMed] [PMC]

70.

Xia J, Hu H, Xue W, Wang XS, Wu S. The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay. J Enzyme Inhib Med Chem. 2018;33:525–35. [DOI] [PubMed] [PMC]

71.

Leus NGJ, van der Wouden PE, van den Bosch T, Hooghiemstra WTR, Ourailidou ME, Kistemaker LE, et al. HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity. Biochem Pharmacol. 2016;108:58–74. [DOI] [PubMed] [PMC]

72.

Chen Y, He R, Chen Y, D’Annibale MA, Langley B, Kozikowski AP. Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors. ChemMedChem. 2009;4:842–52. [DOI] [PubMed]

73.

Suzuki T, Kasuya Y, Itoh Y, Ota Y, Zhan P, Asamitsu K, et al. Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly. PLoS One. 2013;8:e68669. [DOI] [PubMed] [PMC]

74.

Marson CM, Matthews CJ, Atkinson SJ, Lamadema N, Thomas NSB. Potent and selective inhibitors of histone deacetylase-3 containing chiral oxazoline capping groups and a N-(2-aminophenyl)-benzamide binding unit. J Med Chem. 2015;58:6803–18. [DOI] [PubMed]

75.

Wang LZ, Ramírez J, Yeo W, Chan MY, Thuya WL, Lau JY, et al. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013;8:e54522. [DOI] [PubMed] [PMC]

76.

Mulder GJ, Meerman JH. Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: the role of N,O-sulfonation in chemical carcinogenesis of aromatic amines. Environ Health Perspect. 1983;49:27–32. [DOI] [PubMed] [PMC]

77.

Yeo W, Chan SL, Mo FK, Chu CM, Hui JW, Tong JH, et al. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer. 2015;15:395. [DOI] [PubMed] [PMC]

78.

Mahmud I, Liao D. Microarray gene expression profiling reveals potential mechanisms of tumor suppression by the class I HDAC-selective benzoylhydrazide inhibitors. Genom Data. 2015;5:257–9. [DOI] [PubMed] [PMC]

79.

Li X, Jiang Y, Peterson YK, Xu T, Himes RA, Luo X, et al. Design of hydrazide-bearing HDACIs based on panobinostat and their p53 and FLT3-ITD dependency in antileukemia activity. J Med Chem. 2020;63:5501–25. [DOI] [PubMed] [PMC]

80.

McClure JJ, Zhang C, Inks ES, Peterson YK, Li J, Chou CJ. Development of allosteric hydrazide-containing class I histone deacetylase inhibitors for use in acute myeloid leukemia. J Med Chem. 2016;59:9942–59. [DOI] [PubMed] [PMC]

81.

Wang Y, Stowe RL, Pinello CE, Tian G, Madoux F, Li D, et al. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases. Chem Biol. 2015;22:273–84. [DOI] [PubMed] [PMC]

82.

HDAC inhibitor compounds and methods of treatment. Geneva: World Intellectual Property Organization (WIPO); c2015 [cited 2022 Nov 15]. Available from: https://patentimages.storage.googleapis.com/a6/4c/5a/55023bc0bea45f/WO2015153516A1.pdf

83.

Mahmud I, Tian G, Wang J, Stowe R, Huo Z, Zhang Y, et al. Abstract 4718: SR-4370, a potent and selective inhibitor of class I HDACs, suppresses AR signaling and in vivo prostate tumor growth. Cancer Res. 2019;79:4718. [DOI]

84.

Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002;62:4916–21. [PubMed]

85.

Baud MGJ, Leiser T, Haus P, Samlal S, Wong AC, Wood RJ, et al. Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. J Med Chem. 2012;55:1731–50. [DOI] [PubMed]

86.

Bowers A, West N, Taunton J, Schreiber SL, Bradner JE, Williams RM. Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. J Am Chem Soc. 2008;130:11219–22. [DOI] [PubMed] [PMC]

87.

Hong J, Luesch H. Largazole: from discovery to broad-spectrum therapy. Nat Prod Rep. 2012;29:449–56. [DOI] [PubMed] [PMC]

88.

He X, Hui Z, Xu L, Bai R, Gao Y, Wang Z, et al. Medicinal chemistry updates of novel HDACs inhibitors (2020 to present). Eur J Med Chem. 2022;227:113946. [DOI] [PubMed]

89.

Liu J, Yu Y, Kelly J, Sha D, Alhassan AB, Yu W, et al. Discovery of highly selective and potent HDAC3 inhibitors based on a 2-substituted benzamide zinc binding group. ACS Med Chem Lett. 2020;11:2476–83. [DOI] [PubMed] [PMC]

90.

Liu J, Kelly J, Yu W, Clausen D, Yu Y, Kim H, et al. Selective class I HDAC inhibitors based on aryl ketone zinc binding induce HIV-1 protein for clearance. ACS Med Chem Lett. 2020;11:1476–83. [DOI] [PubMed] [PMC]

91.

Tamanini E, Miyamura S, Buck IM, Cons BD, Dawson L, East C, et al. Fragment-based discovery of a novel, brain penetrant, orally active HDAC2 inhibitor. ACS Med Chem Lett. 2022;13:1591–7. [DOI] [PubMed] [PMC]